Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161584 · ClinicalTrials.gov registry record
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A clinical trial of Geographic Atrophy, sponsored by Apellis Pharmaceuticals.
- Active
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT06161584 is a study of Geographic Atrophy that is active but no longer recruiting, run by Apellis Pharmaceuticals. The registered enrollment target is 300 participants, above the 211-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (42% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06161584, a study of Geographic Atrophy, is active but no longer recruiting, sponsored by Apellis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Conditions Studied
Interventions
- DRUG Pegcetacoplan
Study Locations (20)
California
- California Retina Consultants (01-026) - Bakersfield
- Retina-Vitreous Associates Medical Group (01-020) - Beverly Hills
- Illinois Retina Associates (01-035) - Fullerton
- Retinal Consultants Medical Group Inc (01-008) - Modesto
- Retina Consultants San Diego Inc. (01-018) - Poway
- California Retina Consultants (01-027) - Santa Barbara
- Bay Area Retina Associates (01-005) - Walnut Creek
Maryland
- The Retina Care Center (01-023) - Baltimore
- Cumberland Valley Retina Consultants, P.C. (01-002) - Hagerstown
- Mid Atlantic Retina Specialist (01-029) - Hagerstown
Georgia
- South East Retina Center, PC (01-030) - Augusta
- Georgia Retina (01-032) - Marietta
New Jersey
- Mid Atlantic Retina Research (01-014) - Cherry Hill
- Mid Atlantic Retina (01-031) - Cherry Hill
New York
- OCLI Research Department (01-007) - Oceanside
- Long Island Vitreoretinal Consultants (01-013) - Westbury
Colorado
- Colorado Retina Associates, PLLC (01-011) - Lakewood
Florida
- Retina Specialty Institute (01-019) - Pensacola
Illinois
- Illinois Retina Associates (01-037) - Oak Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2027-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161584
The ClinicalTrials.gov registry entry for NCT06161584 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 211-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (42% higher). The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT06161584 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Maryland, Georgia.
Frequently Asked Questions
What is clinical trial NCT06161584 about?
NCT06161584 is a clinical study titled "A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration". A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
What is the current status of trial NCT06161584?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2023-09-28. Estimated completion is 2027-06.
What conditions does trial NCT06161584 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT06161584?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT06161584?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161584 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.